

Azmiro (testosterone cypionate)

Fax completed form to: (855) 840-1678 If this is an URGENT request, please call (800) 882-4462 (800.88.CIGNA)

PHYSICIAN INFORMATION			PATIENT INFORMATION				
* Physician Name: Specialty:			*Due to privacy regulations we will not be able to respond via fax with the outcome of our review unless all asterisked (*) items on this				
Specialty:	DEA,	INPLOT TIN.	form are complete	*			
Office Contact Person:			* Patient Name:				
Office Phone:			* Cigna ID:		* Date of Birth:		
Office Fax:			* Patient Street Address:				
Office Street Address:			City:	Sta	ate:	Zip:	
City:	State:	Zip:	Patient Phone:	I			
Urgency:							
Standard Urgent (In checking this box, I attest to the fact that applying the standard review time frame may seriously jeopardize the customer's life, health, or ability to regain maximum function)							
Medication requested:							
AZMIRO 200mg/mL Pref	illed Syringe in	Oil for Injection					
Dose:	Freque	ncy of therapy:	Duration of therapy:				
What is your patient's current Please provide clinical supportinent patient history).					les include past	medications tried,	
Where will this medication be obtained? <pre> CVS Caremark</pre>						n vendor	
Facility and/or doctor di	ispensing and	d administering n	nedication:				
Facility Name: State:				Tax ID#:			
Address (City, State, Zip Co	de):						
Where will this drug be	administered	?					
☐ Patient's Home ☐ Hospital Outpatient				Physician's Off Other (please s			
NOTE: Per some Cigna plans, infusion of medication MUST occur in the least intensive, medically appropriate setting. Is this patient a candidate for re-direction to an alternate setting (such as alternate infusion site, physician's office, home) with assistance of a Specialty Care Options Case Manager? Yes No (provide medical necessity rationale):							
Is the requested medication the patient?	for a chronic or	long-term condition	for which the prescri	ption medicatio	n may be neces	ssary for the life of ☐ Yes ☐ No	

Diagnosis related to use:	ICD10:				
] Hypogonadism (Primary or Secondary) in Males [Testicular Hypofunction/Low Testosterone with Symptoms]. Note: males are efined as individuals with the biological traits of a male, regardless of the individual's gender identity or gender expression.					
Delayed Puberty or Induction of Puberty in Males. Note: males are defined as individuals with the biological traits of a male, egardless of the individual's gender identity or gender expression.					
Gender-Dysphoric/Gender-Incongruent Persons; Persons Undergoing Female-To-Male (FTM) Gender Reassignment (that is, Endocrinologic Masculinization). Note: In this context, the specified gender is defined as follows: males are defined as individuals the biological traits of a male, regardless of the individual's gender identity or gender expression; females are defined as individual with the biological traits of a female, regardless of the individual's gender identity or gender expression.					
To Enhance Athletic Performance					
☐ other (please specify):					
Clinical Information:					
Is this a new start or continuation of therapy? If your patient has already begun treatment with drug samples, please choose "new start of therapy". new start continuation of therapy					
(if gender dysphoric, incongruent, reassignment) Is this drug being prescribed by, or in physician who specializes in the treatment of transgender patients?	consultation with, an endocrinologist or a ☐ Yes ☐ No				
(if hypogonadism) Has the patient had persistent signs and symptoms of androgen definitiation of any testosterone therapy)? Note: Signs and symptoms of androgen deficie progressive decrease in muscle mass, osteoporosis, and loss of libido.					
(if hypogonadism) Is this initial therapy or is the patient currently receiving Testosteron ☐ Initial therapy	e Therapy?				
 Currently receiving testosterone therapy None of the above or unknown 					
□ None of the above or unknown	surements, each taken in the early morning, on				
 None of the above or unknown If hypogonadism and initial therapy or unknown: Has the patient had TWO pre-treatment serum testosterone (total or bioavailable) mea 	Yes No				
 None of the above or unknown If hypogonadism and initial therapy or unknown: Has the patient had TWO pre-treatment serum testosterone (total or bioavailable) meatwo separate days? 	☐ Yes ☐ No ory reference values? ☐ Yes ☐ No -testosterone); 2. Testosterone enanthate ne and strength, date(s) taken and for how long, or adverse reactions your patient experienced.				
 None of the above or unknown If hypogonadism and initial therapy or unknown: Has the patient had TWO pre-treatment serum testosterone (total or bioavailable) meatwo separate days? Were the TWO serum testosterone levels BOTH low, as defined by the normal laborat The covered alternatives are: 1. Testosterone cypionate intramuscular injection (Depo- intramuscular injection (Delatestryl). For the alternatives tried, please include drug nan and what the documented results were of taking each drug, including any intolerances 	☐ Yes ☐ No ory reference values? ☐ Yes ☐ No -testosterone); 2. Testosterone enanthate he and strength, date(s) taken and for how long, or adverse reactions your patient experienced. ug.				
If hypogonadism and initial therapy or unknown: Has the patient had TWO pre-treatment serum testosterone (total or bioavailable) meatwo separate days? Were the TWO serum testosterone levels BOTH low, as defined by the normal laborat The covered alternatives are: 1. Testosterone cypionate intramuscular injection (Depointramuscular injection (Delatestryl). For the alternatives tried, please include drug namand what the documented results were of taking each drug, including any intolerances For the alternatives NOT tried, please provide details why your patient can't try that drug the patient tried one of the alternatives, but it didn't work Per the information provided above, which of the following is true for your patient in regime the patient tried one of the alternatives, but it didn't work	☐ Yes ☐ No ory reference values? ☐ Yes ☐ No -testosterone); 2. Testosterone enanthate he and strength, date(s) taken and for how long, or adverse reactions your patient experienced. ug.				
None of the above or unknown If hypogonadism and initial therapy or unknown: Has the patient had TWO pre-treatment serum testosterone (total or bioavailable) meatwo separate days? Were the TWO serum testosterone levels BOTH low, as defined by the normal laborate. The covered alternatives are: 1. Testosterone cypionate intramuscular injection (Depointramuscular injection (Delatestryl). For the alternatives tried, please include drug name and what the documented results were of taking each drug, including any intolerances. For the alternatives NOT tried, please provide details why your patient can't try that drug the patient tried one of the alternatives, but it didn't work The patient tried one of the alternatives, but they did not tolerate it The patient cannot try one of these alternatives because of a contraindication to this Other.	☐ Yes ☐ No ory reference values? ☐ Yes ☐ No etestosterone); 2. Testosterone enanthate he and strength, date(s) taken and for how long, or adverse reactions your patient experienced. Jg.				

Additional Pertinent Information: (All diagnoses) Please provide any additional pertinent clinical information, including: if the patient is currently on the requested drug (with dates of use) and how they have been receiving it (for example: samples, out of pocket).
Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan or insurer its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.
Prescriber Signature: Date:
Save Time! Submit Online at: www.covermymeds.com/main/prior-authorization-forms/cigna/ or via SureScripts in your EHR.
Our standard response time for prescription drug coverage requests is 5 business days. If your request is urgent, it is important that you call us to expedite the request. View our Prescription Drug List and Coverage Policies online at cigna.com.

v030125

1

"Cigna" is a registered service mark, and the "Tree of Life" logo is a service mark, of Cigna Intellectual Property, Inc., licensed for use by Cigna Corporation and its operating subsidiaries. All products and services are provided by or through such operating subsidiaries and not by Cigna Corporation. Such operating subsidiaries include, for example, Cigna Health and Life Insurance Company and Cigna Health Management, Inc. Address: Cigna Pharmacy Services, PO Box 42005, Phoenix AZ 85080-2005